Hosted on MSN

Rhythm Pharmaceuticals anticipates IMCIVREE launch in acquired hypothalamic obesity with $416M cash position

David Meeker, Chairman, President & CEO, highlighted "strong growth and continued momentum during the third quarter as we prepare to launch IMCIVREE in acquired hypothalamic obesity pending FDA ...
CNBC

Meeker: Tariffs won't hit us hard, but they pressure the whole sector

Dr. David Meeker, CEO of Rhythm Pharma, says tariffs won't directly impact them but could stress the biotech sector. He warns FDA layoffs may slow drug approvals for rare diseases. Got a confidential ...